Spyre Therapeutics, Inc. (SYRE) Q4 2024 Annual Earnings
SYRE·Reported February 27, 2025·Before market open
Diluted EPS came in at $-0.81, beat the $-0.89 consensus by $0.08.
Diluted EPS
$-0.81beat by $0.08
Consensus: $-0.89
Financial Snapshot
Trailing eight quarters through Q4 2024
Q4 2024 Earnings FAQ
Common questions about Spyre Therapeutics, Inc.'s Q4 2024 earnings report.
Spyre Therapeutics, Inc. (SYRE) reported Q4 2024 earnings on February 27, 2025 before market open.
Spyre Therapeutics, Inc. reported diluted EPS of $-0.81 for Q4 2024.
EPS beat the consensus estimate of $-0.89 by $0.08.
You can read the 10-K periodic report (0001636282-25-000020) directly on SEC EDGAR. The filing index links above go to sec.gov.